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This study aimed to evaluate the progress in reduction of prevalence of anemia in rural Australia. It also investigates the prevalence
of hypoviscosity in anaemia with a view to determine the fraction of anaemic patients at risk of drug-inducible exacerbation of
anemia. Archived clinical pathology data (N = 130, 354) for the period of 1999 to 2008 were utilized. The prevalence of anemia and
hypoviscosity was evaluated by working out (i) the number that fell within anemia definition as a percentage of the population and
(ii) the number that fell within hypoviscosity definition as a percentage of anemic patients. The prevalence in anemic diabetes and
dyslipidaemia was further determined. There was progressive reduction in anemia from 6.1% to 3.2% over the ten years period.
Prevalence of anemia is statistically significantly higher in males than in females (P < 0.0001), but protein level is lower in anemic
females than in anemic males (P < 0.01). The results further show that up to 75% of anemic patients may benefit from NSAID
or salicylates. This paper highlights diﬀerences between genders. It suggests more concerted eﬀort in men’s health and speculates a
new factor to investigate in women’s health.
1. Introduction
There are a range of possible complications of anaemia. For
example, it can predispose certain therapies to worsen bleed-
ing complications. A perspective in practice that requires
further acknowledgement perhaps is the risk of bleeding
and/or exacerbated anaemia. Bleeding as a cause of anaemia
is very well known and may not be dwelt much upon. When
the issue of complications of anaemia comes, the points
that easily come to mind are reduced oxygen transport by
the blood, which feedforward to tissue hypoxia and fatigue.
Others are reduced endurance or exercise capabilities and
secondary organ dysfunction such as heart disease [1].
One potential complication and a confounding factor
that is omitted in the above list is hypoviscosity syndrome.
It is associated with high salicylates level and low platelet
count [2] and synonymous to high international normalized
ratio that contraindicates anticoagulant and antiplatelet
therapies [3]. Thus, it is of particular importance for chronic
disease patients such as diabetes and dyslipidaemia. While
antiplatelet therapies such as aspirin and aphaeresis such as
plasmapheresis are used to reduce blood stasis, “stickiness”
or viscosity in order to improve flow rate, hypoviscosity is a
state where the flow is quite normal, or nonsteroidal anti-
inflammatory drug (NSAID) and antiplatelet could cause
the adverse eﬀect of bleeding [4, 5]. Blood hypoviscosity
can also be defined as opposite to hyperviscosity syndrome
[6]. It results mainly from anaemia and hypoproteinaemia
[7–9]. Based on the rationale for therapeutic management of
hyperviscosity, the implication is that any patient with hypo-
viscosity syndrome may not require therapy that may further
reduce blood viscosity. For instance, when considering fur-
ther bleeding risk such as in sickle cell anaemia and systemic
lupus erythematosis where salicylates and/or NSAID therapy
can cause stomach bleeding and exacerbate the anaemia that
is associated with the disease condition [10, 11].
Given the concerns of adverse eﬀects of therapies and
the attendant need for evidence of indication or otherwise,
it follows that evidence of hypoviscosity translates to con-
traindication for such therapy. As yet, hypoviscosity is not
clinically assessed. Therefore, prevalence of hypoviscosity
associated with anaemia is unknown. Anaemia is a condition
that has undoubtedly attracted attention long time ago, and
it continues to be a thing of health concern especially in
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Table 1: Hematocrit thresholds for definition of anemia.
Age & gender Rural pathology WHO
Children <5 years 34 33
Children 5–<12 years 35 35
Children 12–15 years 36 36
Men >15 years 36 39
Women >15 years 32 36
Pregnant Women 32 33
women [12]. It is a complication involved in a very wide
range of disease [13–16]. It is presumed that knowledge of
the prevalence of concurrent hypoviscosity in anemia will
benefit future planning and targeted management aimed at
avoiding exacerbation.
Aim. This study evaluates the reduction in prevalence of
anemia in rural Australia. Further, it investigates the preva-
lence of anemia and concurrent hypoviscosity in diabetes and
dyslipidaemia patients. The latter objective is with a view to
speculate the fraction of these patients who may be at risk of
bleeding and exacerbated anemia.
2. Materials and Methods
This work is part of a Translational Biomedical Science
Research initiative. It is supported materially by the Albury
South West Pathology, a unit of Western Pathology Cluster
of NSW Health Australia. The Ethics Committee of the
Area Health Service granted request through the Opera-
tions Manager for the use of deidentified data. Ten years
deidentified archived clinical pathology data for the period
of January 1999 to December 2008 constitutes the database
[17]. Selection was limited to those that were concomitantly
tested for haematocrit and total proteins from the same
phlebotomy collection time. WBV at high shear stress
was determined from haematocrit and total proteins as
previously published [18].
Specific to the community/population being studied,
Albury’s South West Pathology reference range for haemat-
ocrit were 0.36–0.49 for men and 0.32–0.46 for women, as
well as serum total protein being 60–80 g/L for both men
and women. These were used to determine that abnormal
low WBV is <13.7 CPs for females and <14.2 CPs for
males [19]. It was acknowledged that prevalence of anemia
depends on the haematocrit thresholds used in the definition
[20]. Therefore, the World Health Organization’s (WHO)
haematocrit thresholds used to define anemia was noted for
the diﬀerent age ranges diﬀered from the rural pathology’s
cutoﬀ lines (Table 1).
In this study deidentified patients have been used. As
the outcome of the study provides no direct or immediate
benefit to participant, contact with patients or their clinicians
was not made. The implication is that selection of diabetes
and dyslipidaemia subjects were limited to those who had
hemoglogin-A1c (HbA1c) and lipids test, respectively.
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Figure 1: Prevalence of anemia in general population of patients.
∗Anemia according to regional pathology is adult male with either
“Hb < 130 g/L” or “hct < 36%”; adult females “Hb < 115 g/L” or
“hct < 32%”.
Statistics: First, data for the entire population of patients
who visited rural Australian pathology service were sorted
into females and males on a yearly basis. Comparative
prevalence of anaemia and hypoviscosity between female
and male groups was determined and compared. The
determination of prevalence followed a simple process of (i)
sorting each group by descending level of haematocrit, (ii)
highlighting and working out the number that fell within
anemia definition as a percentage of the population, (iii)
resorting of those highlighted as anemic by descending level
of WBV, and (iv) working out the number that fell within
hypoviscosity definition as a percentage of anemic patients.
The Comparison was performed by Student’s t-test.
Secondly, prevalence of anemia and risk of adverse
bleeding eﬀect of drugs in diabetes and dyslipidaemia
patients were determined. All cases selected as anemic in the
10 years data sets of male and female groups were separately
pooled and ranked by age. Children and teenagers were
excluded using World Health Organization’s age brackets
regarding definition of anemia (Table 1). The prevalence of
concurrent hypoviscosity in the subgroups was evaluated by
repeating the first three steps of the process performed for the
general population. Statistical analyses were performed using
Microsoft excel analysis tool.
3. Results
The female population included “n = 117, 746”, out of
which 2,796 had anemia. Themale population included “n =
112, 608”, out of which 6,283 had anemia (Table 2). There
is evidence of progressive reduction in anemia over the ten
years period from average of 6.1% in 1999 down to 3.2% by
2008 (Figure 1). It is observed that prevalence is statistically
significantly higher in males than in females (P < 0.0001).
Evaluation of hypoviscosity concurrence shows that (i)
prevalence of hypoviscosity also progressively decreased over
the years from average of 3.4% in 1999 down to 1.0% in
2008 (Table 2). The prevalence is greater in males than in
females (Figure 2; P < 0.01), but much greater in anemic
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Table 2: Numbers of anaemia with confounding hypoviscosity among females and males.
Females Males
N Anaemic Hypo-WBV N Anaemic Hypo-WBV
1999 4449 184 112 4418 358 185
2000 9374 306 181 8980 767 392
2001 11089 332 187 10546 767 370
2002 11291 299 166 11321 580 286
2003 11454 235 120 10717 550 230
2004 12334 306 176 11653 735 276
2005 12677 248 108 11984 616 230
2006 14278 294 126 13338 593 222
2007 15175 300 137 14610 644 229
2008 15625 292 120 15041 675 194
WBV: whole blood viscosity.
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Figure 2: Prevalence of hypoviscosity in general population of
patients.
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Figure 3: Prevalence of hypoviscosity in anemic patients. ∗Anemia
according to regional pathology is adult male with either “Hb <
130 g/L” or “hct < 36%”; adult females “Hb < 115 g/L” or “hct <
32%”.
subpopulations and statistically significantly more in females
subpopulation than in males (Figure 3, P < 0.01). Further
evaluation regarding the average levels of total protein over
the ten years period showed it is consistently and statistically
Table 3: Statistics of total protein levels (g/L) in anemic females and
males.
(a) Overall descriptive statistics
Females Males
Mean (g/L) 62 64
Median (g/L) 62 65
SD 11 10
Minimum (g/L) 23 24
Maximum (g/L) 182 130
Count 2796 6283
(b) Mean protein levels (g/L) by year
Year Females Males
1999 61 62
2000 59 62
2001 61 63
2002 60 62
2003 63 63
2004 61 64
2005 63 65
2006 64 64
2007 63 65
2008 64 66
significantly lower in the anemic female group compared to
the anemic male group (Table 3; P < 0.01)
The second analysis was for the special consideration
to anemic diabetes and dyslipidaemia patients. The anemic
male population included “n = 6283”, out of which “n =
6, 007” were adults. Others were children and teenagers.
Among the adults, 1,367 were tested for lipid profile, of
which 130 had dyslipidaemia indicated by total cholesterol
>5.5mmol/L. 571 were tested for hemoglogin-A1c, which
was used as indication of ongoing diabetes disease man-
agement. 146 were reported as poorly controlled diabetes
(HBA1c > 9%). The anemic female population included
“n = 2, 796”, out of which “n = 2, 744” were adults. Others
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Figure 4: Prevalence of hypoviscosity in anemic diabetes and
dyslipidaemia.
were children and teenagers. Among the adults, 539 were
tested for lipid profile, of which 54 had total cholesterol
>5.5mmol/L. 173 were tested for HbA1c, of which 49 were
reported as poorly controlled diabetes (HBA1c > 9%).
On further evaluation for hypoviscosity concurrence
with anemia, it is observed that there is at least 24% preva-
lence of hypoviscosity concurrent with anemia in patients
who have diabetes or dyslipidaemia patients (Figure 4).
4. Discussion
The first objective of this study was to determine progress
in reduction of anemia over a period of ten years using
pathology-based evidence. Given that prevalence of anemia
depends on the haematocrit thresholds used in the definition
[20], it was noted that the World Health Organization
thresholds for diagnosis of anemia were diﬀerent from the
reference ranges used by the pathology (Table 1). Therefore,
discretion was employed to use pathology’s reference values
in order to avoid underestimation of the prevalence of
anemia in adults.
The results in Figure 1 provide laboratory-based evi-
dence to indicate that there is real progress and success in
the eﬀorts towards reducing anemia. If females and males
are combined, there is evidence of progressive reduction
in anemia over the ten years period from average of 6.1%
in 1999 down to 3.2% by 2008 (Figure 1). It also show,
however, that the prevalence of anemia is consistently and
statistically significantly higher in males than in females
(Table 2; P < 0.0001). This observation probably reflects the
greater eﬀorts to eradicate anemia in women compared to
men. It highlights the need for men’s health to emulate the
attention given to anemia from women [12].
Evaluation of hypoviscosity concurrence shows that the
prevalence of hypoviscosity is also progressively decreasing
just as anemia is decreasing and that it is more in males
than in females (Figure 2; P < 0.01). This observation
indicates the impact of anemia as a contributing factor
to blood viscosity. However, it is interesting to note that
percentage prevalence of hypoviscosity is more than ten
folds in the anemic subpopulation compared to the general
patient population. Further, hypoviscosity is observed to be
persistently statistically significantly more in anemic females
than in anemic males (Figure 3, P < 0.01). That is, although
anemia and hypoviscosity are separately more prevalent
in the males over the ten years period, the fraction of
anemic women who have concurrence of hypoviscosity is
significantly more than in males.
The observation presented in Table 3 demonstrates that
average total protein levels for the groups are on the side of
normalcy and significantly lower in anemic females than in
anemic males (Table 3; P < 0.01). The salient implication
is that hypoproteinaemia is more in anemic females than
in males. Hypoproteinaemia is the biochemistry status that
would drive a physiological state of hypoviscosity [18], which
in turn drives pathological bleeding complication [21].
Perhaps, it is pertinent to diﬀerentiate (i) low haema-
tocrit, as the sign that medication is causing loss of
blood [22, 23] from (ii) low proteinaemia as a condition
that would drive hypoviscosity enroute further bleeding
complication.Thus, if given equal number of men and
women suﬀering anemia, more of the anemic women have
a confounding condition of hypoproteinaemiathat would
make them likely to suﬀer bleeding complications.
Anemia and hypoproteinaemia have been identified as
a symptom complex mainly in cystic fibrosis [24, 25] and
requiring medical nutritional supplement for the man-
agement [26]. The observation presented in Figure 4 is
translated to over 24% percent of anemic diabetes and dyslip-
idaemia patients having confounding factor that predisposes
them to risk of bleeding, if treated with antiplatelet or
NSAID. The clinical importance is that it reflects the fraction
of anemic patients who may require consideration for thera-
pies that would not exacerbate existing anemia condition.
Perhaps, it is pertinent to mention that there are alterna-
tives to drugs. A case has been reported of woman who com-
plained of bleeding bruises as side eﬀect to aspirin. Over a
long time, her General Practitioner did not receive any pa-
thology report that contraindicates the therapy. The patient
attended a diabetes research screening clinic where WBV was
tested and identified to be in the abnormal low range. Based
on the WBV result, patient resorted to nutrition and physical
activities as alternative therapeutic measures [27].
Neither WBV nor hypoviscosity syndrome is as yet
routinely assessed in clinical practice. Therefore, this report
is speculative and suggestive. The premise is strong that
blood is less sticky, antiplatelet therapy could cause too much
bleeding and exacerbate any existing anemia [4, 21]. The
novelty of this report is in threefolds: (i) pathology-based
evidence that a substantial number of anemic patients have
confounding factor (hypoviscosity driven by proteinaemia)
that could predispose them to risk of bleeding and exacer-
bation of anemia, (ii) in addition haematocrit, protein level
from routine liver function test can be utilized to determine
concurrence of hypoviscosity to rule of risk of exacerbating
anemia, and (iii) previous report indicated that 97.5% of
cases investigated for chronic diseases could benefit from
antiplatelet medication [28], but this study indicates only up
to 75% of anemic patients.
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5. Conclusion
This paper indicates that hypoviscosity driven by low
proteinaemia is highly prevalent in anemia. The speculation
and suggestion here are that laboratory monitoring of stasis
using proteinaemia and/or WBV measures should provide
evidence-based pathology for risk of exacerbating anemia in
anemic patients.
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